7 completed, 1 not yet recruiting. 8 Phase 1, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 8 | Completed 7, Not yet recruiting 1 |
| Phase 2 | 1 | Not yet recruiting 1 |
Follow Ectodermal Dysplasia: new trials by email Literature Review of Ectodermal Dysplasia trials Research Report on Ectodermal Dysplasia
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Epidermal Growth Factor Receptor Inhibition for Keratinopathies Erlotinib - Epidermolytic Ichthyosis, Palmoplantar Keratoderma | Phase 1 / Phase 2 | Not yet recruiting | Northwestern University | 44 | 2027-07-01 | 2026-08-03 |
| Assessment of KM-001 - Safety, Tolerability, and Efficacy in Patients With PPPK1 or PC KM-001 cream 1% 12 weeks treatment., Physical Examination, Vital Signs - Punctate Palmoplantar Keratoderma Type 1, Pachyonychia Congenita | Phase 1 | Completed | Orvida Pharma (formerly Kamari Pharma) | 18 | 2023-03-06 | 2025-01-15 |
| Study Designed to Evaluate Safety and Efficacy of 1% Topical Formulation of KM-001 on Type 1 Punctate Palmoplantar Keratoderma or Pachyonychia Congenita Diseases Serum chemistry, Hematology, Urinalysis - Punctate Palmoplantar Keratoderma Type 1, Pachyonychia Congenita | Phase 1 | Completed | Orvida Pharma (formerly Kamari Pharma) | 14 | 2022-07-17 | 2025-01-07 |
| Assess the Safety, Tolerability and Pharmacokinetics of AZD5055 Following Single and Multiple Ascending Doses in Healthy Participants AZD5055, Placebo - Idiopathic Pulmonary Fibrosis | Phase 1 | Completed | AstraZeneca | 63 | 2021-11-18 | 2024-05-16 |
| Effect of Broccoli Sprout Extract on Keratinocyte Differentiation in Normal Skin Jojoba oil with broccoli sprout extract, Jojoba oil (placebo) - Epidermolysis Bullosa Simplex, Pachyonychia Congenita | Phase 1 | Completed | Johns Hopkins University | 5 | 2015-09-01 | 2017-12-06 |
| Topical Sirolimus for the Treatment of Pachyonychia Congenita (PC) 1% sirolimus cream (TD201 1%) - Pachyonychia Congenita | Phase 1 | Completed | TransDerm, Inc. | 15 | 2014-01-01 | 2016-10-07 |
| A Phase 1, Open-label, Multicenter, Safety and Pharmacokinetic Study of EDI200 EDI200 - X-linked Hypohidrotic Ectodermal Dysplasia | Phase 1 | Completed | Edimer Pharmaceuticals | 6 | 2012-05-01 | 2013-11-27 |
| Study of TD101, a Small Interfering RNA (siRNA) Designed for Treatment of Pachyonychia Congenita TD101, Normal saline (placebo) - Pachyonychia Congenita | Phase 1 | Completed | Pachyonychia Congenita Project | 1 | 2008-01-01 | 2008-11-19 |
Pachyonychia Congenita (6) · Keratosis palmoplantaris papulosa (2) · Ectodermal Dysplasia 1, Anhidrotic (1) · Epidermolysis Bullosa Simplex (1) · Focal Dermal Hypoplasia (1) · Hyperkeratosis, Epidermolytic (1) · Idiopathic Pulmonary Fibrosis (1) · Keratoderma, Palmoplantar (1)
Abnormalities, Multiple (8) · Congenital Abnormalities (8) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (8) · Genetic Diseases, Inborn (8) · Skin Abnormalities (8) · Skin Diseases (8) · Skin Diseases, Genetic (8) · Skin and Connective Tissue Diseases (8) · Nail Diseases (6) · Genetic Diseases, X-Linked (2) · Bone Diseases (1) · Bone Diseases, Developmental (1) · Dysostoses (1) · Epidermolysis Bullosa (1)
Hematologic Tests (2) · Pain Measurement (2) · Physical Examination (2) · Therapeutics (2) · Urinalysis (2) · Vital Signs (2) · Erlotinib Hydrochloride (1) · Fc-EDA (1) · KPNA1 protein, human (1) · Saline Solution (1) · jojoba wax (1)
Orvida Pharma (formerly Kamari Pharma) (2) · AstraZeneca (1) · Edimer Pharmaceuticals (1) · Johns Hopkins University (1) · Northwestern University (1) · Pachyonychia Congenita Project (1) · TransDerm, Inc. (1)
United States (6) · Israel (1) · United Kingdom (1)
Amy Paller (1) · Bernard Cohen, MD (1) · James Maynard, MD (1) · Ophir Klein, MD, PhD (1) · Roger L Kaspar, PhD (1) · Sancy A Leachman, MD, PhD (1)